Understanding inherited genetic risk variants in IKZF1 to understand and prevent childhood B-ALL
Official title: Dissecting the role of common and rare risk variants in IKZF1 in B-cell acute lymphoblastic leukemia predisposition and pathogenesis
Funded at Boston Children's Hospital · NIH-11281299 · Data updated 2026-11-12
A doctor-scientist at Boston Children’s Hospital is studying how inherited genetic differences in IKZF1 may cause or shape childhood B-ALL, with the goal of guiding better prevention and treatment in the future.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $274,676 |
| NIH project number | 1K08CA308788-01 |
| Project ID | NIH-11281299 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children diagnosed with B-cell acute lymphoblastic leukemia or those at familial risk due to IKZF1 variants may benefit from future translational advances.
✕Less likely to help
This research is primarily focused on genetics and mechanisms and may not directly benefit patients in the short term.
What this research studies
This grant aims to map how common and rare IKZF1 genetic variants influence the development of B-cell acute lymphoblastic leukemia in children. Through genetic and functional analyses, the project will link inherited variants to biological effects in B-cell development and leukemia initiation. The work will combine computational genetics with laboratory studies to validate how these variants alter IKZF1 function and contribute to disease risk. The long-term goal is to create a translational framework that connects genetic risk to mechanisms that could be targeted by future therapies or prevention strategies. The emphasis is on early disease origins and how to move from variant discovery to understood biology that can inform care.
Why it matters
Potential benefit: If successful, the project could reveal new targets for prevention or early intervention in childhood B-ALL and improve our understanding of why some children develop leukemia.
How similar studies have gone: Prior studies have linked IKZF1 variants to leukemia risk, with ongoing work translating genetic findings into mechanistic insight, though complete clinical translation is still emerging.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Wahlster, Lara — Boston Children's Hospital
- Study coordinator: Wahlster, Lara
Related research
Other NIH-funded projects on the same topics.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
-
Genomics of childhood ALL across diverse populations
A large international study will look at why children everywhere get acute lymphoblastic leukemia and how genetics may influence risk.
-
Combinatorial targeting for high-risk B-cell ALL treatment
A research effort at West Virginia University is exploring a combination therapy for adult B-cell acute lymphoblastic leukemia using targeted gene silencing and a small-molecule compound to improve treatment in patients.
-
Understanding why Latino children have a higher risk of childhood ALL
This project looks at why Latino children are more likely to develop acute lymphoblastic leukemia and whether genetic ancestry plays a role, with the goal of improving prevention and outcomes.
-
Targeting obesity to improve survival for children with ALL
A new approach explores whether reducing obesity-related factors can make chemotherapy work better for kids with acute lymphoblastic leukemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.